The Third Signal: Why Retatrutide Is Changing the Science of Metabolic Peptides

The Next Chapter Is About More Than Appetite

For much of the modern history of metabolic medicine, appetite regulation has been at the center of peptide research.

The discovery and development of glucagon-like peptide-1 receptor agonists demonstrated that targeting hormonal communication between the intestine, pancreas, and brain could produce substantial physiological effects.

The next major advance involved combining GLP-1 receptor activity with another hormonal pathway: glucose-dependent insulinotropic polypeptide, or GIP.

Now, researchers are investigating a third component: glucagon.

Glucagon is traditionally associated with raising blood glucose. It is released by pancreatic alpha cells and helps maintain glucose availability during fasting by stimulating hepatic glucose production.

Why, then, would scientists deliberately activate the glucagon receptor while developing compounds intended to improve metabolic regulation?

That question sits at the heart of retatrutide research.

Retatrutide, also known by its development identifier LY3437943, is a synthetic peptide engineered to activate three receptor systems: GIP, GLP-1, and glucagon.

On September 29, 2026, researchers published pivotal Phase 3 findings in The New England Journal of Medicine. A second Phase 3 study appeared in The Lancet, providing further evidence in people with type 2 diabetes.

Together, these publications represent an important advance in the clinical evidence available for triple-receptor peptide research.

But the most scientifically interesting question is not simply how much weight changed in these trials. It is what the results reveal—and what they still cannot reveal—about the contribution of three distinct hormonal pathways.

1. Three Receptors, Three Biological Histories

The human body regulates energy balance through an interconnected network of hormones, neural circuits, and metabolic organs.

GLP-1 is secreted primarily by intestinal enteroendocrine L cells in response to nutrient exposure. Its biological functions include glucose-dependent stimulation of insulin secretion, modulation of gastric emptying, and participation in neural pathways involved in appetite regulation.

GIP is released from intestinal K cells and contributes to glucose-dependent insulin secretion. Its receptor is expressed in several tissues, including pancreatic islets and adipose tissue.

Glucagon originates principally from pancreatic alpha cells. Its classical function is to help maintain glucose availability during periods when dietary glucose is not entering the circulation.

It acts particularly on the liver, where it promotes processes such as glycogen breakdown and gluconeogenesis.

Yet glucagon's biology extends beyond glucose production.

Experimental research has investigated its influence on lipid metabolism, amino-acid turnover, hepatic signaling, and energy expenditure.

This creates an intriguing possibility: a molecule activating all three receptors may generate a physiological response that differs from activating any single pathway independently.

However, the receptors do not necessarily produce a simple additive effect. Their interactions depend on receptor activity, tissue distribution, metabolic state, and the pharmacological characteristics of the compound itself.

Three-receptor activation is a molecular design strategy—not proof that every receptor contributes equally to the final biological outcome.

2. The Molecular Engineering Behind Retatrutide

Retatrutide is not a mixture of three separate peptide drugs. It is one engineered peptide molecule with activity at three different receptor systems.

Its design incorporates structural modifications that influence receptor pharmacology and prolong its duration of activity.

An important 2022 study in Cell Metabolism described the discovery and early experimental characterization of LY3437943.

Researchers examined its receptor activity, pharmacological properties, and metabolic effects across preclinical models and early human investigations.

The compound showed activity at the GIP, GLP-1, and glucagon receptors, providing the foundation for later clinical development.

Rather than simply reproducing a naturally occurring hormone, researchers can modify peptide structure to influence receptor selectivity, signaling potency, molecular stability, and pharmacokinetics.

However, retatrutide has different potencies across its three targets, complicating attempts to assign a particular clinical effect to a single receptor.

Read the original molecular discovery study in Cell Metabolism.

3. Why the Glucagon Receptor Is So Interesting

Glucagon occupies an unusual position in metabolic research.

Its role in raising blood glucose might seem incompatible with the objectives of many metabolic therapies.

But glucagon receptor signaling also influences processes that extend beyond glycemic regulation.

In experimental systems, glucagon-related signaling has been associated with changes in substrate utilization, hepatic lipid metabolism, and energy expenditure.

Researchers have therefore investigated whether glucagon receptor activity can be combined with incretin signaling to produce a favorable overall metabolic response.

The proposed rationale is that GLP-1 and GIP receptor activity may contribute to glucose regulation and food-intake effects while glucagon receptor activation influences additional metabolic pathways.

The substantial weight changes observed with retatrutide do not independently prove that glucagon receptor activation increased energy expenditure in humans.

To establish that mechanism, investigators would need appropriately designed studies measuring energy expenditure and accounting for changes in body composition.

A March 2026 scoping review in Obesity Reviews examined human studies of GLP-1 receptor agonists and combination therapies.

The authors emphasized that more rigorous human research is needed to determine how these therapies influence energy expenditure and metabolic adaptation.

The glucagon receptor is therefore a compelling research target precisely because important mechanistic questions remain open.

4. The First Major Clinical Signal

In June 2023, a Phase 2 trial published in The New England Journal of Medicine provided an early indication of retatrutide's clinical activity.

The study enrolled 338 adults with obesity or overweight accompanied by a weight-related condition.

Participants were randomly assigned to different retatrutide treatment groups or placebo, with follow-up extending to 48 weeks.

At 48 weeks, the study reported an estimated average body-weight reduction of 24.2% in the highest-dose group, compared with 2.1% for placebo.

But the study also identified important tolerability concerns. Gastrointestinal adverse events were common, and increases in heart rate were observed.

The trial was relatively small and could not establish long-term clinical outcomes.

Nevertheless, it provided a rationale for moving into larger Phase 3 investigations.

Read the original Phase 2 trial.

5. September 2026: The TRIUMPH-1 Results

On September 29, 2026, the peer-reviewed TRIUMPH-1 study was published in The New England Journal of Medicine.

The Phase 3 trial randomized 2,339 adults with obesity and without diabetes to retatrutide or placebo over 80 weeks.

The investigators assessed body-weight change and selected outcomes involving knee osteoarthritis and obstructive sleep apnea.

Mean Body-Weight Reduction at Week 80

Source: TRIUMPH-1, treatment-regimen estimand, week 80. These values describe randomized clinical trial outcomes and are not dosing recommendations.

The findings demonstrated statistically significant differences between the principal retatrutide treatment groups and placebo.

The study also reported improvements in knee osteoarthritis pain scores and obstructive sleep apnea measures within relevant participant subgroups.

However, these findings do not establish that retatrutide independently repairs joint tissue or directly addresses every mechanism contributing to sleep apnea.

The trial also did not establish long-term cardiovascular event reduction, mortality benefit, or effects on human lifespan.

Read the September 2026 TRIUMPH-1 publication.

6. Why Two Different Weight-Loss Numbers Appear

One source of confusion surrounding the 2026 results is the difference between the reported 25.0% and 28.3% figures.

Both refer to TRIUMPH-1, but they represent different statistical approaches.

The 25.0% result comes from the treatment-regimen estimand in the peer-reviewed publication.

This approach attempts to estimate the effect of assignment to treatment regardless of whether participants fully continued their assigned regimen.

The 28.3% figure reported in the May 2026 company announcement uses an efficacy estimand, which estimates outcomes under different assumptions about treatment continuation.

Neither number should be presented without its statistical context.

Cross-trial differences in populations, duration, statistical methods, and treatment conditions can influence reported results.

A larger percentage in one trial does not, by itself, establish superiority over another compound.

7. Retatrutide and Type 2 Diabetes: TRIUMPH-2

TRIUMPH-2 investigated a different population.

Published online on September 29, 2026, in The Lancet, the study enrolled 1,152 adults with obesity or overweight and type 2 diabetes.

Participants were randomized to retatrutide or placebo over 80 weeks.

Using the treatment-regimen estimand, researchers reported mean body-weight reductions of 18.8% in the highest-dose group and 5.1% with placebo.

The study also identified improvements in glycemic control.

These findings are significant because type 2 diabetes introduces additional metabolic complexity.

Insulin resistance, pancreatic beta-cell function, background glucose-lowering medication, and differences in metabolic physiology can influence outcomes.

But safety findings deserve equal attention.

Gastrointestinal events were common. Hypotension and dysesthesia—abnormal sensory experiences—were reported more frequently in several retatrutide groups than with placebo.

Longer-term safety assessment remains necessary.

Read the TRIUMPH-2 study in The Lancet.

8. Does Triple-Receptor Activity Explain the Results?

The answer is not yet fully established.

Retatrutide activates three receptor systems, and its clinical studies demonstrate substantial effects on body weight and other metabolic measures.

But determining the precise contribution of each receptor remains challenging.

Researchers investigate these questions through comparative molecular pharmacology and experimental models in which individual receptor pathways can be altered or selectively inhibited.

Human clinical trials introduce additional complexity.

A compound's effects depend on exposure, receptor distribution, tissue sensitivity, and changes in physiology over time.

For example, a reduction in food intake can alter circulating hormones and energy expenditure.

Weight loss itself can produce metabolic adaptations.

These secondary changes make it difficult to identify the contribution of an individual receptor from body-weight measurements alone.

The current evidence supports the importance of multi-receptor peptide pharmacology without resolving every mechanistic question.

9. What the Evidence Does Not Establish

The available clinical trials do not establish that retatrutide reverses biological aging.

They do not demonstrate that the compound extends human lifespan.

They also do not prove that glucagon receptor activation independently accounts for the observed magnitude of weight reduction.

Nor do the findings establish the long-term safety of unsupervised use or formulations obtained outside controlled clinical development.

As of October 27, 2026, retatrutide remains an investigational compound without FDA approval.

A planned regulatory submission is not a regulatory approval, and the outcome of a future decision cannot be assumed.

The existence of a promising clinical research program does not establish that a laboratory research material is suitable for human administration.

10. Why Analytical Research Standards Matter

The expanding complexity of peptide pharmacology places greater importance on molecular identity and analytical documentation.

Researchers investigating a synthetic peptide need to establish that the material under examination corresponds to the intended compound.

Depending on the research objective, relevant information may include molecular identity, purity, stability, and batch traceability.

These characteristics help establish the integrity of experimental materials.

They do not establish clinical safety, therapeutic efficacy, or equivalence to a pharmaceutical formulation.

At Royal Peptides, laboratory materials are supplied under a research-only framework.

The company's COA Verification Library provides available batch-specific analytical records, while its FAQ provides further information about the company's research materials and policies.

Royal Peptides' research materials are distinct from the investigational pharmaceutical formulations used in clinical trials. No equivalence should be assumed.

11. The Questions That Will Define the Next Generation

The development of triple-receptor peptides has opened several important scientific questions.

One concerns receptor balance.

How much activity at each receptor is necessary to produce a particular biological response?

Another concerns tissue specificity.

Does the same molecular design generate different responses depending on the metabolic condition of the tissue?

A third question involves energy expenditure.

Can researchers establish whether glucagon receptor activation contributes meaningfully to changes in human energy balance beyond reductions in food intake?

The relationship between peptide pharmacology and body composition also requires further investigation.

Changes in total body weight do not fully describe changes in fat mass, lean tissue, or metabolic function.

Future studies using rigorous body-composition measurements and appropriate physiological methods may help distinguish these effects.

Longer-term clinical outcomes will be equally important.

Researchers will need to understand the durability of observed effects, the consequences of treatment discontinuation, and whether changes in intermediate metabolic measures translate into meaningful differences in disease outcomes.

The Bigger Picture: Peptide Science Is Becoming More Integrated

Retatrutide represents an important change in how scientists approach metabolic peptide design.

The objective is no longer necessarily to reproduce the activity of one natural hormone.

Instead, researchers are investigating whether a single engineered molecule can engage several complementary signaling systems.

This strategy introduces new opportunities. It also creates new scientific challenges.

The more receptor systems a compound influences, the more carefully researchers must investigate its mechanisms, tissue-specific effects, and safety.

The September 2026 Phase 3 publications provide substantial evidence that retatrutide produces measurable clinical effects in the populations studied.

They do not resolve every question about how those effects arise.

The most important development may not be the discovery that three receptors can be activated by one peptide. It may be the growing recognition that metabolic regulation cannot be fully understood through a single hormonal pathway.

GLP-1 provided one major insight. GIP expanded that understanding. Glucagon now adds another layer.

The future of metabolic peptide science may depend on understanding not only what each pathway does independently, but how their activities interact across the entire biological system.

Scientific References

1. Jastreboff AM, Kaplan LM, Davies MJ, et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2604169
2. Bellido V, le Roux CW, Ekinci EI, et al. (2026). Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2). The Lancet. DOI: 10.1016/S0140-6736(26)01861-1
3. Jastreboff AM, Kaplan LM, Frias JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
4. Coskun T, Urva S, Roell WC, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metabolism. DOI: 10.1016/j.cmet.2022.07.013
5. Vieira FT, Deng Z, Muller MJ, et al. (2026). Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review. Obesity Reviews. DOI: 10.1111/obr.70116
6. ClinicalTrials.gov. TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants With Obesity. Clinical Trial NCT05929066

About the Royal Peptides Research Journal

The Royal Peptides Research Journal is an editorial publication produced by Royal Peptides, exploring developments in peptide chemistry, metabolic biology, molecular signaling, and emerging peptide research.

The publication emphasizes original scientific literature, transparent sourcing, and careful distinctions between laboratory findings, clinical trial evidence, and regulatory decisions.

Commercial Disclosure

Royal Peptides is a commercial supplier of laboratory research materials, including synthetic peptides. The publisher therefore has a financial interest in topics related to peptide science.

Royal Peptides did not conduct, sponsor, or participate in the clinical studies discussed in this article.

The investigational retatrutide formulations evaluated in pharmaceutical clinical trials are not equivalent to commercially supplied laboratory research materials.

Scientific and Medical Disclaimer

This publication is intended exclusively for scientific and educational purposes.

It does not provide medical advice, treatment recommendations, dosing instructions, or guidance for administering investigational compounds.

Retatrutide remains investigational as of October 27, 2026. Clinical outcomes discussed apply only to the study populations, formulations, and experimental conditions described in the cited research.

Royal Peptides research materials are intended strictly for legitimate laboratory research and are not for human or veterinary use.